Comparison of silicone versus polyurethane ureteral stents

Standard

Comparison of silicone versus polyurethane ureteral stents : A prospective controlled study. / Gadzhiev, Nariman; Gorelov, Dmitry; Malkhasyan, Vigen; Akopyan, Gagik; Harchelava, Revaz; Mazurenko, Denis; Kosmala, Christina; Okhunov, Zhamshid; Petrov, Sergei.

In: BMC Urology, Vol. 20, No. 1, 10, 03.02.2020.

Research output: Contribution to journal › Article › peer-review

Author

Gadzhiev, Nariman ; Gorelov, Dmitry ; Malkhasyan, Vigen ; Akopyan, Gagik ; Harchelava, Revaz ; Mazurenko, Denis ; Kosmala, Christina ; Okhunov, Zhamshid ; Petrov, Sergei. / Comparison of silicone versus polyurethane ureteral stents : A prospective controlled study. In: BMC Urology. 2020 ; Vol. 20, No. 1.

BibTeX

@article{e2ac808d836f4237b42b0c3f2bfd0f85,

title = "Comparison of silicone versus polyurethane ureteral stents: A prospective controlled study",

abstract = "Background: Approximately 80% of patients with indwelling ureteral stents experience stent related symptoms (SRS). We believe SRS can be reduced through altering the composition of ureteral stents to a less firm material. Therefore, we aim to compare modern silicone and polyurethane ureteral stents in terms of SRS intensity and safety. Methods: From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (R{\"u}sch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey 1 h after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group. Results: A total of 50 patients participated in the study, control group A consisted of 20 patients and experimental group B consisted of 30 patients. Participants in group B, silicone ureteral stents, demonstrated significantly lower mean values of VASP 2 weeks prior to stent removal and promptly before stent removal (p = 0.023 and p = 0.014, respectively). No other comparisons between the two groups were statistically significant. Conclusions: Compared to polyurethane ureteral stents, silicone ureteral stents are associated with lower body pain intensity assessed by VASP 2 weeks before stent removal and at the time of stent removal. Trial registration: Current Controlled Trials NCT04000178. Retrospectively registered on June 26, 2019.",

keywords = "Polyurethane, Quality of life, Silicone, Stent-related symptoms, Ureteral stent",

author = "Nariman Gadzhiev and Dmitry Gorelov and Vigen Malkhasyan and Gagik Akopyan and Revaz Harchelava and Denis Mazurenko and Christina Kosmala and Zhamshid Okhunov and Sergei Petrov",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = feb,

day = "3",

doi = "10.1186/s12894-020-0577-y",

language = "English",

volume = "20",

journal = "BMC Urology",

issn = "1471-2490",

publisher = "BioMed Central Ltd.",

number = "1",

}

RIS

TY - JOUR

T1 - Comparison of silicone versus polyurethane ureteral stents

T2 - A prospective controlled study

AU - Gadzhiev, Nariman

AU - Gorelov, Dmitry

AU - Malkhasyan, Vigen

AU - Akopyan, Gagik

AU - Harchelava, Revaz

AU - Mazurenko, Denis

AU - Kosmala, Christina

AU - Okhunov, Zhamshid

AU - Petrov, Sergei

PY - 2020/2/3

Y1 - 2020/2/3

N2 - Background: Approximately 80% of patients with indwelling ureteral stents experience stent related symptoms (SRS). We believe SRS can be reduced through altering the composition of ureteral stents to a less firm material. Therefore, we aim to compare modern silicone and polyurethane ureteral stents in terms of SRS intensity and safety. Methods: From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (Rüsch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey 1 h after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group. Results: A total of 50 patients participated in the study, control group A consisted of 20 patients and experimental group B consisted of 30 patients. Participants in group B, silicone ureteral stents, demonstrated significantly lower mean values of VASP 2 weeks prior to stent removal and promptly before stent removal (p = 0.023 and p = 0.014, respectively). No other comparisons between the two groups were statistically significant. Conclusions: Compared to polyurethane ureteral stents, silicone ureteral stents are associated with lower body pain intensity assessed by VASP 2 weeks before stent removal and at the time of stent removal. Trial registration: Current Controlled Trials NCT04000178. Retrospectively registered on June 26, 2019.

AB - Background: Approximately 80% of patients with indwelling ureteral stents experience stent related symptoms (SRS). We believe SRS can be reduced through altering the composition of ureteral stents to a less firm material. Therefore, we aim to compare modern silicone and polyurethane ureteral stents in terms of SRS intensity and safety. Methods: From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (Rüsch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey 1 h after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group. Results: A total of 50 patients participated in the study, control group A consisted of 20 patients and experimental group B consisted of 30 patients. Participants in group B, silicone ureteral stents, demonstrated significantly lower mean values of VASP 2 weeks prior to stent removal and promptly before stent removal (p = 0.023 and p = 0.014, respectively). No other comparisons between the two groups were statistically significant. Conclusions: Compared to polyurethane ureteral stents, silicone ureteral stents are associated with lower body pain intensity assessed by VASP 2 weeks before stent removal and at the time of stent removal. Trial registration: Current Controlled Trials NCT04000178. Retrospectively registered on June 26, 2019.

KW - Polyurethane

KW - Quality of life

KW - Silicone

KW - Stent-related symptoms

KW - Ureteral stent

UR - http://www.scopus.com/inward/record.url?scp=85078940601&partnerID=8YFLogxK

U2 - 10.1186/s12894-020-0577-y

DO - 10.1186/s12894-020-0577-y

M3 - Article

C2 - 32013936

AN - SCOPUS:85078940601

VL - 20

JO - BMC Urology

JF - BMC Urology

SN - 1471-2490

IS - 1

M1 - 10

ER -

ID: 88009453